Eli Lilly's Obesity Pill Shows Promise in Phase 3 Trial

Kilder

• Nature: Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins - Nature
• Nature: DeepMVP: deep learning models trained on high-quality data accurately predict PTM sites and variant-induced alterations - Nature
• Statnews: Eli Lilly’s obesity pill helped lower weight, blood sugar in key Phase 3 trial - statnews.com
• Statnews: Akeso says its closely watched drug improved patient survival in a lung cancer trial - statnews.com
• Fiercebiotech: Lilly rounds out oral GLP-1 approval bid with phase 3 obesity win for patients with diabetes - Fierce Biotech
• Biopharmadive: RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial - BioPharma Dive

Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.